var data={"title":"Eltrombopag: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Eltrombopag: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/370490?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=eltrombopag-drug-information\" class=\"drug drug_general\">see &quot;Eltrombopag: Drug information&quot;</a> and <a href=\"topic.htm?path=eltrombopag-patient-drug-information\" class=\"drug drug_patient\">see &quot;Eltrombopag: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815164\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6809750\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Promacta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12817171\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Revolade</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819159\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Colony Stimulating Factor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hematopoietic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Thrombopoietic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819164\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=eltrombopag-drug-information\" class=\"drug drug_general\">see &quot;Eltrombopag: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Do not use eltrombopag to normalize platelet counts. Due to possible bioavailability differences with product formulations, platelet counts should be assessed weekly for 2 weeks when switching between oral suspension and tablets, then follow monthly monitoring.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Pediatric:<b> Chronic immune (idiopathic) thrombocytopenia (ITP):</b> <b>Note:</b> Use the lowest dose to achieve and maintain platelet count &ge;50,000/mm<sup>3</sup> as needed to reduce the risk of bleeding. Discontinue if platelet count does not respond to a level that avoids clinically important bleeding after 4 weeks at the maximum daily dose of 75 mg. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Children 1 to &lt;6 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Initial:</i> Oral: 25 mg once daily (no dosage adjustment required for patients of East Asian ancestry)   </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Dosage adjustment based on platelet response:</i> Adjust dose to achieve/maintain platelet count &ge;50,000/mm<sup>3</sup> as necessary to reduce bleeding risk; maximum daily dose: 75 mg/<b>day</b>. Monitor platelet count weekly until stabilizes and then monthly; additional monitoring may be necessary based on response or any changes in product formulation (oral suspension/tablets).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">In the key multicenter international efficacy trial (Bussel 2015), dosage was adjusted based on the following protocol: Limited data available:   </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">If platelet count &lt;50,000/mm<sup>3</sup> (&ge;2 weeks after treatment initiation or a dose increase): Increase daily dose by 12.5 mg increments at 2-week intervals; maximum daily dose: 75 mg/<b>da</b>y once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">If platelet count &ge;200,000/mm<sup>3</sup> and &le;400,000/mm<sup>3</sup> (at any time): Reduce daily dose by 12.5 mg; reassess platelet count in 2 weeks  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">If  platelet count &gt;400,000/mm<sup>3</sup>: Withhold doses; assess platelet count twice weekly; when platelet count &lt;150,000/mm<sup>3</sup>, resume with the daily dose reduced by 12.5 mg  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">If platelet count &gt;400,000/mm<sup>3</sup> after 2 weeks at the lowest dose: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Children &ge;6 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Initial:</i> 50 mg once daily (25 mg once daily for patients of East Asian ethnicity [eg, Chinese, Japanese, Korean, Taiwanese])  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Dosage adjustment based on platelet response:</i> Adjust dose to achieve/maintain platelet count &ge;50,000/mm<sup>3</sup> as necessary to reduce bleeding risk; maximum daily dose: 75 mg/<b>day</b>. Monitor platelet count weekly until stabilizes and then monthly; additional monitoring may be necessary based on response or any changes in product formulation (oral suspension/tablets).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">If platelet count &lt;50,000/mm<sup>3</sup> (&ge;2 weeks after treatment initiation or a dose increase): Increase daily dose by 25 mg (if taking 12.5 mg once daily, increase dose to 25 mg once daily prior to increasing the dose amount by 25 mg daily); maximum daily dose: 75 mg/<b>day</b> once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">If platelet count &ge;200,000/mm<sup>3</sup> and &le;400,000/mm<sup>3</sup> (at any time): Reduce daily dose by 25 mg (if previous dose 25 mg once daily, decrease dose to 12.5 mg once daily); reassess platelet count in 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">If platelet count &gt;400,000/mm<sup>3</sup>: Withhold doses; assess platelet count twice weekly; when platelet count &lt;150,000/mm<sup>3</sup>, resume with the daily dose reduced by 25 mg (if previous dose 25 mg once daily, resume with 12.5 mg once daily) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">If platelet count &gt;400,000/mm<sup>3</sup> after 2 weeks at the lowest dose: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Chronic immune (idiopathic) thrombocytopenia (ITP):</b> Oral: <b>Note:</b> Use the lowest dose to achieve  and maintain platelet count &ge;50,000/mm<sup>3</sup> as needed to reduce the risk of bleeding. Discontinue if platelet count does not respond to a level that avoids clinically important bleeding after 4 weeks at the maximum daily dose of 75 mg. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Initial:</i> 50 mg once daily (25 mg once daily for patients of East Asian ethnicity [eg, Chinese, Japanese, Korean, Taiwanese]); dose should be titrated based on platelet response. Maximum dose: 75 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Dosage adjustment based on platelet response: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Platelet count &lt;50,000/mm<sup>3</sup> (&ge;2 weeks after treatment initiation or a dose increase): Increase daily dose by 25 mg (if taking 12.5 mg once daily, increase dose to 25 mg once daily prior to increasing the dose amount by 25 mg daily); maximum: 75 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Platelet count &ge;200,000/mm<sup>3</sup> and &le;400,000/mm<sup>3</sup> (at any time): Reduce daily dose by 25 mg (if taking 25 mg once daily, decrease dose to 12.5 mg once daily); reassess in 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Platelet count &gt;400,000/mm<sup>3</sup>: Withhold dose; assess platelet count twice weekly; when platelet count &lt;150,000/mm<sup>3</sup>, resume with the daily dose reduced by 25 mg (if taking 25 mg once daily, resume with 12.5 mg once daily) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Platelet count &gt;400,000/mm<sup>3</sup> after 2 weeks at the lowest dose: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Chronic hepatitis C-associated thrombocytopenia:</b> Oral: <b>Note:</b> Use the lowest dose to achieve the target platelet count necessary to initiate and maintain antiviral therapy (peginterferon and ribavirin) or to avoid dose reductions of peginterferon during antiviral therapy. Discontinue when antiviral therapy is stopped. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial</i>: 25 mg once daily; dose should be titrated based on platelet response. Maximum dose: 100 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment based on platelet response:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &lt;50,000/mm<sup>3</sup> (after at least 2 weeks): Increase daily dose by 25 mg every 2 weeks; maximum dose: 100 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &ge;200,000/mm<sup>3</sup> and &le;400,000/mm<sup>3</sup> (at any time): Reduce daily dose by 25 mg; reassess in 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &gt;400,000/mm<sup>3</sup>: Withhold dose; assess platelet count twice weekly; when platelet count &lt;150,000/mm<sup>3</sup>, resume with the daily dose reduced by 25 mg (if taking 25 mg once daily, resume with 12.5 mg once daily) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &gt;400,000/mm<sup>3</sup> after 2 weeks at the lowest dose: Discontinue treatment  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe aplastic anemia:</b> Oral: <b>Note:</b> Use the lowest dose to achieve and maintain hematologic response. Hematologic response may take up to 16 weeks and requires dose titration. Discontinue therapy if hematologic response is not achieved after 16 weeks of treatment, for excessive platelet responses or for liver function abnormalities. Consider discontinuing if new cytogenetic abnormalities are observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial:</i> 50 mg once daily (25 mg once daily for patients of East Asian ethnicity); dose should be titrated based on platelet response. Maximum dose: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment based on platelet response:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &lt;50,000/mm<sup>3</sup> (&ge;2 weeks after treatment initiation or a dose increase): Increase daily dose by 50 mg (if taking 25 mg once daily, increase dose to 50 mg once daily prior to increasing the dose amount by 50 mg daily); maximum: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &ge;200,000/mm<sup>3</sup> and &le;400,000/mm<sup>3</sup> (at any time): Reduce daily dose by 50 mg; reassess in 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &gt;400,000/mm<sup>3</sup>: Withhold dose for 1 week; when platelet count &lt;150,000/mm<sup>3</sup>, resume with the daily dose reduced by 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Platelet count &gt;400,000/mm<sup>3</sup> after 2 weeks at the lowest dose: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For patients who achieve trilineage response, including transfusion independence, lasting 8 weeks, may reduce the dose by 50%. If counts remain stable after 8 weeks at the reduced dose, discontinue and monitor blood counts. If platelet counts drop to &lt;30,000/mm<sup>3</sup>, hemoglobin to &lt;9 g/dL, or ANC to &lt;500/mm<sup>3</sup>, may reinitiate at the prior effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Baseline hepatic impairment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <b>Chronic ITP: </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Children 1 to &lt;6 years: There are no dosage adjustments provided by the manufacturer; however, dose adjustments should be considered; use with caution. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Children &ge;6 years, Adolescents, and Adults: <b>Note:</b> In patients with ITP and hepatic impairment, wait 3 weeks (instead of 2 weeks) after therapy initiation or subsequent dosage changes prior to increasing dose.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Mild, moderate, or severe impairment (Child-Pugh classes A, B, or C): Initial: 25 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Patients of East Asian ethnicity with hepatic impairment (Child-Pugh classes A, B, or C): Initial: 12.5 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Chronic hepatitis C-associated thrombocytopenia:</b> Adults: Initial: No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Severe aplastic anemia: </b>Adults: Mild, moderate, or severe impairment (Child-Pugh classes A, B, or C): Initial: 25 mg once daily  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Hepatic impairment during treatment:</i> Children &ge;1 year, Adolescents, and Adults:  ALT levels &ge;3 times the upper limit of normal (ULN) in patients with normal hepatic function or &ge;3 times baseline in those with preexisting transaminase elevations and which are progressive, persistent (&ge;4 weeks), accompanied by increased direct bilirubin, or accompanied by clinical signs of liver injury or evidence of hepatic decompensation: Discontinue treatment. Hepatotoxicity may recur with retreatment after therapy interruption, but if determined to be clinically beneficial, may cautiously resume treatment; monitor ALT weekly during dosage titration; permanently discontinue if liver function test elevations persist, worsen, or recur. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815297\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Promacta: 12.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Promacta: 25 mg [contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Promacta: 50 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Promacta: 75 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815166\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29871551\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Promacta oral suspension: FDA approved August 2015; anticipated availability is currently unknown. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874620\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022291s019lbl.pdf#page=29&amp;token=eaXha647EZQS+Q5tdj4oFsYzilIUMeu6BHW2daI2197ehfLF4bfSDaRTpaT6gMV4beSPKJenJj7Q7X+IWw8NtOU0LLYc0gRgGNoUsC6Oy/sTlO0AXe/WkIV3yBOAe+HN&amp;TOPIC_ID=108893\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022291s019lbl.pdf#page=29</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819165\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer on an empty stomach, 1 hour before or 2 hours after a meal. Do not administer concurrently with antacids, foods high in calcium, or minerals (eg, iron, calcium, aluminum, magnesium, selenium, zinc); separate by at least 4 hours. Do not administer more than one dose within 24 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow tablets whole; do not crush.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: After administration, place any waste in the trash (not sink drain); clean supplies by removing plunger from oral syringe, rinse bottle, lid, syringe, and plunger under running water and air-dry (bottle may stain, this is normal); wash hands with soap and water. If powder or suspension spills during administration, consider wearing \tdisposable gloves during spill clean-up to avoid staining skin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815200\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Once reconstituted (if not used immediately), the suspension may be stored for a maximum of 30 minutes between 20&deg;C and 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Discard the mixture if not used within 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). If present, do not remove desiccant. Dispense in original bottle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819160\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had insufficient response to corticosteroids, immune globulin, or splenectomy (FDA approved in ages &ge;1 year and adults); treatment of thrombocytopenia associated with chronic hepatitis C (CHC) to allow the initiation and maintenance of interferon-based therapy (FDA approved in adults); treatment of severe aplastic anemia in patients who have had insufficient response to immunosuppressive therapy (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815189\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema (adults), portal vein thrombosis, thrombosis (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Brain disease (adults), chills (adults), fatigue (adults), headache (adults), insomnia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (adults), pruritus (adults), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (children and adolescents), decreased appetite (adults), diarrhea (more common in adults), nausea (adults), toothache (children and adolescents), vomiting (adults), xerostomia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests (adults), ascites (adults), hyperbilirubinemia (adults), increased serum alkaline phosphatase (adults), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Influenza (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain (adults), musculoskeletal pain (adults), myalgia (adults), paresthesia (adults), weakness (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract (more common in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, flu-like symptoms (adults), nasopharyngitis (children and adolescents), oropharyngeal pain, pharyngitis (adults), rhinitis (children and adolescents), rhinorrhea (children and adolescents), upper respiratory tract infection (more common in children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (more common in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hemorrhage, skin discoloration (including hyperpigmentation and skin yellowing), thrombotic thrombocytopenic purpura (with acute renal failure)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815176\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to eltrombopag or any component of the formulation; severe hepatic impairment (Child-Pugh class C)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815177\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cataract formation: Cataract formation or worsening was observed in clinical trials. Monitor regularly for signs and symptoms of cataracts; obtain ophthalmic exam at baseline and during therapy. Use with caution in patients at risk for cataracts (eg, advanced age, long-term glucocorticoid use).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: </b><b>Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended.</b> Liver enzyme elevations may occur; obtain ALT, AST, and bilirubin prior to treatment initiation, every 2 weeks during adjustment phase, then monthly (after stable dose established). Eltrombopag inhibits UGT1A1 and OATP1B1, which may lead to indirect hyperbilirubinemia; obtain fractionation for elevated bilirubin levels. Repeat abnormal liver function tests within 3 to 5 days; if confirmed abnormal, monitor weekly until resolves, stabilizes, or returns to baseline. Discontinue treatment for ALT levels &ge;3 times the upper limit of normal (ULN) in patients with normal hepatic function, or &ge;3 times baseline (or &gt;5 times ULN; whichever is lower) in those with preexisting transaminase elevations and which are progressively increasing, or persistent (&ge;4 weeks), or accompanied by increased direct bilirubin, or accompanied by clinical signs of liver injury or evidence of hepatic decompensation. Hepatotoxicity may recur with re-treatment after therapy interruption; however, if the benefit of treatment outweighs the hepatotoxicity risk, initiate carefully, and monitor liver function tests weekly during the dose adjustment phase. Permanently discontinue if liver test abnormalities persist, worsen, or recur with rechallenge. In clinical trials, isolated cases of severe liver injury occurred, liver function test abnormalities usually occurred ~3 months after initiation of eltrombopag and resolved with discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Thromboembolism (venous or arterial) may occur with excessive increases in platelet levels. Use with caution in patients with known risk factors for thromboembolism (eg, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease). Thrombotic events, primarily involving the portal venous system, were more commonly seen in eltrombopag-treated chronic hepatitis C patients with thrombocytopenia (when compared to placebo). Thrombotic events (including portal venous thrombosis) were also reported in a study of non-ITP thrombocytopenic patients with chronic liver disease undergoing elective invasive procedures receiving eltrombopag 75 mg once daily. Symptoms of portal vein thrombosis include abdominal pain, nausea, vomiting, and diarrhea. The risk for portal venous thrombosis is increased in thrombocytopenic patients with chronic liver disease receiving 75 mg once daily for 2 weeks as preparation for invasive procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis C infection: <b>[US Boxed Warning]: May increase risk of hepatic decompensation when used in combination with interferon and ribavirin in patients with chronic hepatitis C.</b> In clinical trials, patients with low albumin (&lt;3.5 g/dL) or a Model for End-Stage Liver Disease (MELD) score &ge;10 at baseline had an increased risk of hepatic decompensation; closely monitor these patients during therapy. If antiviral therapy is discontinued for hepatic decompensation according to interferon/ribavirin recommendations, eltrombopag should also be discontinued. Indirect hyperbilirubinemia is commonly observed with eltrombopag when used in combination with peginterferon and ribavirin. In addition, ascites, encephalopathy, and thrombotic events were reported more frequently than placebo in chronic hepatitis C trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Clearance may be reduced in patients with hepatic impairment; use with caution; reduced starting doses are recommended in patients with ITP (except children 1 to 5 years) and severe aplastic anemia who have hepatic impairment (no initial dose reductions are necessary in patients with chronic hepatitis C-related thrombocytopenia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myelodysplastic syndromes: Eltrombopag is not indicated for the treatment of myelodysplastic syndromes (MDS). A clinical trial comparing the combination of azacitidine plus eltrombopag to azacitidine alone in patients with intermediate-1, intermediate-2, or high-risk MDS was terminated due to lack of efficacy and safety concerns (including increased progression to AML). Increased relative risks of death and progression to AML in the eltrombopag arm compared to placebo were observed in the study.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution with renal impairment (any degree) and monitor closely; initial dosage adjustment is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; East-Asian ethnicity (eg, Chinese, Japanese, Korean, Taiwanese): May have greater drug exposure (compared to non-East Asians); therapy should be initiated with lower starting doses in ITP and severe aplastic anemia patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use to normalize platelet counts. <i>ITP:</i> Indicated only when the degree of thrombocytopenia and clinical conditions increase the risk for bleeding in patients with chronic immune ITP; use the lowest dose necessary to achieve and maintain platelet count &ge;50,000/mm<sup>3</sup>. Discontinue if platelet count does not respond to a level to avoid clinically important bleeding after 4 weeks at the maximum recommended dose. <i>Chronic hepatitis C-associated thrombocytopenia:</i> Use only when thrombocytopenia prevents the initiation and maintenance of interferon-based therapy; discontinue if antiviral therapy is discontinued. Safety and efficacy have not been established when combined with direct acting antiviral medications approved for chronic hepatitis C genotype 1 infection therapy. <i>Severe aplastic anemia:</i> Use the lowest dose to achieve and maintain hematologic response. Discontinue if no hematologic response has occurred after 16 weeks of therapy, excessive platelet count responses or important liver test abnormalities. Consider discontinuation if new cytogenetic abnormalities are observed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815843\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP1A2 (minor), CYP2C8 (minor), UGT1A1, UGT1A3; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, OATP1B1/SLCO1B1, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B15, UGT2B7</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815844\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=108893&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any aluminum-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCRP/ABCG2 Substrates: Eltrombopag may increase the serum concentration of BCRP/ABCG2 Substrates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any calcium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May decrease the serum concentration of Eltrombopag.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Eltrombopag may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with eltrombopag and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any multivitamin containing polyvalent cations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any multivitamin containing polyvalent cations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OATP1B1/SLCO1B1 Substrates: Eltrombopag may increase the serum concentration of OATP1B1/SLCO1B1 Substrates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Eltrombopag may increase the serum concentration of Rosuvastatin.  Management: Consideration a preventive 50% reduction in rosuvastatin adult dose when starting this combination; Canadian labeling recommends limiting rosuvastatin to a maximum of 20 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selenium: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any selenium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any zinc-containing product.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815198\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food, especially dairy products, may decrease the absorption of eltrombopag. Management: Take on an empty stomach at least 1 hour before or 2 hours after a meal. Take eltrombopag at least 2 hours before and 4 hours after foods high in calcium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815171\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815172\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adverse effects were observed in animal reproduction studies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Information related to the use of eltrombopag for the treatment of thrombocytopenia in pregnancy is limited (Favier 2017; Purushothaman 2016; Suzuki 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If used in combination with ribavirin, all warnings related to the use of ribavirin and pregnancy and/or contraception should be followed. Refer to the ribavirin monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819166\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombocytopenia due to CHC and chronic ITP: Liver function tests, including ALT, AST, and bilirubin (baseline, every 2 weeks during dosage titration, then monthly; evaluate abnormal liver function tests within 3 to 5 days; monitor weekly until abnormalities resolve, stabilize, or return to baseline or if retreating [not recommended] after therapy interruption for hepatotoxicity); bilirubin fractionation (for elevated bilirubin); CBC with differential and platelet count (weekly at initiation and during dosage titration, then monthly when stable; after cessation, monitor weekly for &ge;4 weeks; when switching between the oral suspension and tablet, monitor platelet counts weekly for 2 weeks, then monthly when stable); peripheral blood smear (baseline and monthly when stable), bone marrow biopsy with staining for fibrosis (if peripheral blood smear reveals abnormality); ophthalmic exam (baseline and during treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe aplastic anemia: CBC with differential and platelets (regularly throughout therapy), liver function tests (regularly throughout therapy); ophthalmic exam (baseline and during treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819167\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Target platelet count (with treatment) of 50,000 to 200,000/mm<sup>3</sup>; platelet life span: 8 to 11 days </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815283\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Eltrombopag is a thrombopoietin (TPO) nonpeptide agonist which increases platelet counts by binding to and activating the human TPO receptor. Activates intracellular signal transduction pathways to increase proliferation and differentiation of marrow progenitor cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815201\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Platelet count increase: Within 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Platelets return to baseline: 1 to 2 weeks after last dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive hepatic metabolism; via CYP 1A2, 2C8 oxidation and UGT 1A1, 1A3 glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: At least 52%; in adults, plasma AUC was increased by 22% with the oral suspension versus tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~21 to 32 hours in healthy individuals; ~26 to 35 hours in patients with ITP</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~59%, 20% as unchanged drug); urine (31%, as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625192\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma eltrombopag apparent clearance following oral administration (CL/F) increased with increasing body weight. East Asian pediatric patients with ITP had approximately 43% higher plasma eltrombopag AUC(0-&tau;) values compared with non-East Asian patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321880\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Promacta Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (30): $5,324.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $5,324.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $9,905.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (30): $14,858.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961943\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Rebozet (ID);</li>\n      <li>Revolad (UA);</li>\n      <li>Revolade (AE, AR, AT, AU, BE, BR, CH, CL, CR, CY, CZ, DK, DO, EE, ES, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bauman JW, Vincent CT, Peng B, et al. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics [published online ahead of print July 27, 2010]. <i>J Clin Pharmacol</i>. 2011;51(5):739-750.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eltrombopag-pediatric-drug-information/abstract-text/20663991/pubmed\" target=\"_blank\" id=\"20663991\">20663991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. <i>Lancet Haematol</i>. 2015;2(8):e315-325.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eltrombopag-pediatric-drug-information/abstract-text/26688484 /pubmed\" target=\"_blank\" id=\"26688484 \">26688484 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bussel JB, Provan D, Shamsi T, et al, &ldquo;Effect of Eltrombopag on Platelet Counts and Bleeding During Treatment of Chronic Idiopathic Thrombocytopenic Purpura: A Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>Lancet</i>, 2009, 373(9664):641-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eltrombopag-pediatric-drug-information/abstract-text/19231632/pubmed\" target=\"_blank\" id=\"19231632\">19231632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 108893 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6815164\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6809750\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12817171\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F25819159\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F25819164\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6815297\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F6815166\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F29871551\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874620\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25819165\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6815200\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F25819160\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6815189\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6815176\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6815177\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F6815843\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6815844\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F6815198\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6815171\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6815172\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25819166\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F25819167\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6815283\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F6815201\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F28625192\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321880\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961943\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/108893|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=eltrombopag-drug-information\" class=\"drug drug_general\">Eltrombopag: Drug information</a></li><li><a href=\"topic.htm?path=eltrombopag-patient-drug-information\" class=\"drug drug_patient\">Eltrombopag: Patient drug information</a></li></ul></div></div>","javascript":null}